Detalles de la búsqueda
1.
Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial.
Br J Cancer
; 130(5): 788-797, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38200233
2.
Late cognitive and adaptive outcomes of patients with neuroblastoma-associated opsoclonus-myoclonus-ataxia-syndrome: A report from the Children's Oncology Group.
Pediatr Blood Cancer
; 71(7): e31039, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38689540
3.
Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I-MIBG in patients with relapsed/refractory neuroblastoma.
Pediatr Blood Cancer
; 71(1): e30743, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37885116
4.
Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531.
Pediatr Blood Cancer
; : e31089, 2024 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38822537
5.
Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report from the Children's Oncology Group.
Pediatr Blood Cancer
; 70(8): e30418, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37199022
6.
Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting.
Cancer
; 128(21): 3775-3783, 2022 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36101004
7.
Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
Pediatr Blood Cancer
; 69(9): e29616, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35188340
8.
Anatomic patterns of relapse and progression following treatment with 131 I-MIBG in relapsed or refractory neuroblastoma.
Pediatr Blood Cancer
; 69(2): e29396, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34662499
9.
Global Neuroblastoma Network: An international multidisciplinary neuroblastoma tumor board for resource-limited countries.
Pediatr Blood Cancer
; 69(4): e29568, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35084087
10.
A safety and feasibility trial of 131 I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study.
Pediatr Blood Cancer
; 68(10): e29117, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34028986
11.
Risk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk Neuroblastoma.
Biol Blood Marrow Transplant
; 25(10): 2031-2039, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31199983
12.
Congenital malformation syndromes associated with peripheral neuroblastic tumors: A systematic review.
Pediatr Blood Cancer
; 66(10): e27901, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31264798
13.
Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
Pediatr Blood Cancer
; 66(8): e27819, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31115156
14.
Neuroblastoma: clinical and biological approach to risk stratification and treatment.
Cell Tissue Res
; 372(2): 195-209, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29572647
15.
Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.
Eur J Nucl Med Mol Imaging
; 45(2): 292-305, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28940046
16.
Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma.
Pediatr Blood Cancer
; 65(5): e26940, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29350464
17.
Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.
Pediatr Blood Cancer
; 65(7): e27023, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29603591
18.
Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
Cancer
; 123(21): 4224-4235, 2017 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28696504
19.
MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
Pediatr Blood Cancer
; 64(11)2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28383813
20.
Comparison of Clinical Features and Outcomes in Patients With Bilateral Versus Unilateral Adrenal Neuroblastoma.
J Pediatr Hematol Oncol
; 39(2): 108-113, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-27820129